Skip to content
OpenCapital
Get started

Vaxcyte, Inc. PCVX Sale of investments

Sale of investments at other companies

Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s sale of investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s sale of investments?
Vaxcyte, Inc. (PCVX) reported sale of investments of $24.88M in Q1 2026.
How has Vaxcyte, Inc.'s sale of investments changed year-over-year?
Vaxcyte, Inc.'s sale of investments decreased by 4.5% year-over-year, from $26.07M to $24.88M.
What is the long-term trend for Vaxcyte, Inc.'s sale of investments?
Over 3 years (2022 to 2025), Vaxcyte, Inc.'s sale of investments has grown at a 129.4% compound annual growth rate (CAGR), from $14.48M to $174.69M.
What does sale of investments mean?
This represents cash inflows from the sale of marketable securities, such as corporate bonds or government debt, classified as available-for-sale. It reflects the company's active management of its liquid investment portfolio.